Cardiovascular Innovation Surge: 18 Breakthrough Devices Enter Expedited Review, Led by Artificial Heart Valves and Ventricular Assist Systems

Dec 30, 2025 08:02 CST Updated 08:02

Medtronic

Medical Device Manufacturer

ForQaly

Minimally Invasive Heart Ventricular Assist Device Developer

PART.01

Latest Announcement! Artificial Heart Valves Lead 18 Innovative Devices into the Approval "Fast Track"

On December 24, 2025, the National Medical Products Administration (NMPA) released the "Public Notice of Review Results for Special Review Applications of Innovative Medical Devices (No. 13, 2025)", proposing to approve 18 projects for entry into the special review process, with a public comment period until January 8, 2026. Among them, the artificial heart valve from Suzhou Heartline Medtech Co., Ltd. was successfully selected, becoming one of the core highlights of this announcement. The selected products cover multiple cutting-edge fields such as cardiovascular, orthopedics, cancer diagnosis, and neurointervention, featuring well-known domestic and international enterprises like Medtronic, Dazhi Bio, and Shih Healthcare. This marks a concentrated surge in the innovation and development of high-end medical devices in China, especially with significant technological breakthroughs in artificial hearts and related valve fields drawing considerable attention.

PART.02

In-Depth Analysis of Core Fields: Innovative Technologies Reshape Medical Scenarios, Artificial Heart Valves Become a Benchmark in the Cardiovascular Field

(1) Cardiovascular Disease Treatment: A Conceptual Breakthrough from "Implantation" to "Absorbable", Artificial Heart Valves Lead the Upgrade

Artificial Heart Valve (Suzhou Heartline Medtech)：As the core highlight product of this public announcement, this artificial heart valve is known as the "star benchmark" in China's cardiovascular innovation field. The product uses high-performance polymer materials and industrial robot automated production processes, which not only significantly enhance the stability and durability of the valve but also optimize its structure to accommodate more patients with complex anatomical structures. Currently, the product has initiated clinical enrollment for surgical aortic valve procedures and is expected to provide safer and more durable treatment options for a wide range of heart valve disease patients in the future, potentially filling the market gap for high-end artificial heart valves in China.

Pulse Ablation System and Catheter (Ronghe Medical):Focusing on the treatment of arrhythmia, precise destruction of abnormal electrical signals is achieved through pulsed field technology, avoiding the risk of thermal injury associated with traditional radiofrequency ablation, and advancing electrophysiological treatment towards "minimally invasive and precise" upgrades.

Implantable Left Ventricular Assist System (ForQaly Medical(Shanghai) Co., Ltd.): As an important innovative product in the field of artificial hearts, this system is implanted through a minimally invasive interventional approach and can effectively assist the left ventricular pumping function in patients with severe heart failure, providing critical support for those awaiting heart transplantation or requiring short-term circulatory assistance. Its lightweight design and precise blood flow regulation technology significantly reduce the risk of postoperative complications, advancing the treatment of severe heart failure towards minimally invasive and personalized solutions.
Three-Branch Aortic Arch Stent System (Lifetech Scientific): Designed for complex aortic arch lesions, it features an integrated three-branch design to simplify the surgical procedure, enhance stent conformity and blood flow reconstruction, and reduce postoperative complications.

(II) Orthopedics and Regenerative Medicine: The Materials Revolution Ushers in the "Implant-Free" Repair Era

Bone Adhesive Material (Hangzhou Yuannang Bio): The world's first biomaterial capable of rapid adhesion in a blood environment, achieving "immediate fixation in wet conditions" for comminuted fractures, avoiding secondary surgeries required for traditional plate and screw removal, and accelerating the fracture healing process.
Tumor Knee Prosthesis (Beijing Leadcom): Utilizes microporous titanium alloy and tantalum metal coating technology, offering high strength and bone compatibility. It provides customized joint replacement solutions for bone tumor patients, enhancing postoperative limb function recovery.
Absorbable Medical Adhesive (Beijing Bohui Ruitong): An alternative to traditional surgical sutures, enabling rapid tissue adhesion and biodegradation, reducing surgical trauma and scar formation. Suitable for minimally invasive surgery scenarios such as laparoscopy and endoscopy.
Absorbable Coils (Shendun Medical): A breakthrough product in the field of neurointervention, made from bio-absorbable materials. After completing the task of vascular embolization, they gradually degrade, addressing the potential risks associated with the long-term presence of traditional metal coils in the body. Suitable for complex lesions such as intracranial aneurysms.

(III) Precision Diagnosis and Treatment of Tumors: Dual-Driven by Early Screening and Intervention Techniques

Tumor Tissue Origin Gene Detection Kit (Nanjing Shihe Medical): Based on combinatorial probe-anchor polymerization sequencing, it accurately identifies the primary tumor origin and metastasis pathways, providing personalized treatment options for advanced cancer patients and filling the clinical gap in multi-omics joint detection in China.
Lung Radiofrequency Ablation System (Hangzhou堃博Bio): Targeting early-stage lung cancer and pulmonary nodules, it precisely inactivates lesions using radiofrequency energy and combines minimally invasive interventional techniques to achieve "one-stop percutaneous puncture treatment," offering a new option for patients unable to undergo surgery.
Hepatocellular Carcinoma Multi-Gene Methylation Combined Detection Kit (Hangzhou Aorui Gene): Integrates multiple biomarkers such as AFP, AFP-L3%, and PIVKA-II to enhance the sensitivity and specificity of early hepatocellular carcinoma screening, supporting early intervention in high-risk populations.

(4) Integration of Cutting-edge Technologies: Neuromonitoring, Intraoperative Navigation, etc. Open a New Chapter in Intelligent Healthcare

Intraoperative Neuromonitoring and Parathyroid Detection Device (Beijing Turing Zhiyi): Real-time monitoring through electrophysiological signals, precise identification of neural and parathyroid tissues, reducing the risk of nerve damage in thyroid and head and neck surgeries, promoting the implementation of the "precision surgery" concept.

PART.03

Special Review Procedure: Building an "Accelerated Pathway" for Innovative Devices to Facilitate the Early Implementation of Artificial Heart Valves

According to the "Special Review Procedure for Innovative Medical Devices," selected products can enjoy green channel services such as "priority testing, priority review, and dedicated liaison," reducing the average approval cycle by 30%-50%. For instance, past cases like Neusoft Medical's photon-counting CT and Quanlan Technology's transcranial electrical stimulation therapy system demonstrate that the special review process not only accelerates product launches but also helps companies optimize R&D pathways and reduce clinical failure risks through early intervention by regulatory experts. Among the 18 projects this time, domestically innovative products represented by artificial heart valves have shown outstanding performance, with domestic companies accounting for over 80% overall. This highlights China's technological breakthrough in transitioning from "catching up" to "running alongside" in the high-end medical device field, especially gaining core competitiveness in the artificial heart and valve segments.

PART.04

Industry Outlook: Innovation Ecosystem Drives Acceleration of China-Made Substitutes, Artificial Heart Sector Becomes Core Breakthrough

The products in this announcement exhibit three major trends:

Material Innovation Dominates: The widespread application of biocompatible materials such as absorbable polymers and magnesium alloys not only drives the transformation of implant devices from "permanent" to "functional degradation," but also enhances the clinical safety of the products.

Precision Medicine Deepens: Integration of Multi-Omics Testing, AI-Assisted Diagnosis, and Interventional Treatment to Achieve "Subtyping Diagnosis and Treatment" for Cancer and Cardiovascular Diseases;

Global Layout: International giants such as Medtronic and Biosense Webster compete alongside Chinese manufacturers, pushing domestic industries to enhance technological barriers and accelerate entry into the global market.

As China advances its "Healthy China 2030" strategy, the special review process for innovative medical devices will continue to deliver policy benefits, supporting breakthroughs in more "chokepoint" technologies such as artificial heart valves, allowing globally leading medical technologies to benefit more patients.

PART.05

Conclusion: The innovation wave led by artificial heart valves is rewriting the landscape of cardiovascular treatment.

The unveiling of these 18 innovative devices is not only a "parade" showcasing corporate R&D capabilities, but also a milestone for China's medical device industry transitioning from manufacturing to "intelligent" manufacturing. The successful inclusion of the artificial heart valve signifies that China has taken its place among the international leaders in this specialized field. It is anticipated that this core innovation and other selected devices will soon be put into practice, rewriting the treatment landscape for cardiovascular diseases through technological breakthroughs and safeguarding human health.